Cysteamine

Cysteamine

SCHEMBL19359042

CC(=O)NCCS.NCCS

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 3/20 0.56
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.48
TSHR P16473 2/20 0.44
ALDH1A1 P00352 2/20 0.43
ADRA1A P35348 1/20 0.39
CYP3A4 P08684 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
BLM P54132 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ESR1 P03372 1/20 0.36
F13A1 P00488 1/20 0.35
MTNR1A P48039 4/20 0.34
MTNR1B P49286 4/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL9299355 0.91 PAOX (0.52) PAOXKDM4EMAPK1HIF1ATSHR
SCHEMBL474178 0.90
SCHEMBL20768364 0.90 KDM4E (0.57) PAOXKDM4EMAPK1HIF1ATSHR
Hydrogen Sulfide SCHEMBL19359044 0.87
SCHEMBL22361778 0.87 KDM4E (0.55) PAOXKDM4EMAPK1HIF1ATSHR
Ammonia Solution, Strong SCHEMBL28356491 0.87
SCHEMBL10545704 0.87
Hydrochloric Acid SCHEMBL3979349 0.87
SCHEMBL10545165 0.87
Ethyl Chloride SCHEMBL29164065 0.81 KDM4E (0.48) PAOXKDM4EMAPK1HIF1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117599029-A Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders 硫创治疗公司 2024-02-27 CN disclosed
US-11786491-B2 Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders THIOGENESIS THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20220040127-A1 COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS THIOGENESIS THERAPEUTICS, INC. 2022-02-10 US disclosed
US-11173135-B2 Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders THIOGENESIS THERAPEUTICS, INC. (US) 2021-11-16 US disclosed
US-20190070132-A1 COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS THIOGENESIS THERAPEUTICS, INC. 2019-03-07 US disclosed
EP-3429573-A1 COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS Thiogenesis Therapeutics, Inc. (US) 2019-01-23 EP disclosed
WO-2017161318-A1 COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS THIOGENESIS THERAPEUTICS, INC. (US) 2017-09-21 WO disclosed